U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. Atomoxetine (marketed as Strattera) Information
  1. Postmarket Drug Safety Information for Patients and Providers

Atomoxetine (marketed as Strattera) Information

Atomoxine (marketed as Strattera) is currently approved in the United States to treat attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults. 

This information reflects FDA’s current analysis of data available to FDA concerning this drug. FDA intends to update this page when additional information or analyses become available 

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax, using the contact information at the bottom of this page.

Related Information

Labeling and Regulatory History from Drugs@FDA

Back to Top